Patents
Sitemap › C07 - Organic chemistry › C07K - Peptides › C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526)
12/2005
12/01/2005WO2005113597A1 Human cxcr3 receptor variants and methods of use
12/01/2005WO2005113596A2 Cell surface receptor isoforms and methods of identifying and using the same
12/01/2005WO2005113595A2 High affinity ny-eso t cell receptor
12/01/2005WO2005113594A1 Selective vpac2 receptor peptide agonists
12/01/2005WO2005113593A1 Selective vpac2 receptor peptide agonists
12/01/2005WO2005113592A2 Interferon-alpha polypeptides and conjugates
12/01/2005WO2005113591A1 Chimeric soluble hyper il-11 and use thereof
12/01/2005WO2005113590A2 Bmp10 propeptides and related methods
12/01/2005WO2005113589A2 Modified antigen-presenting cells
12/01/2005WO2005113588A2 Methods and compositions related to smad anchors for tgfb/bmp receptor activaton
12/01/2005WO2005113587A2 Gene products expressed differentially in tumors and use thereof
12/01/2005WO2005113586A2 Disease-associated proteins
12/01/2005WO2005113585A2 Modified tgf-beta superfamily polypeptides
12/01/2005WO2005113584A1 Methods and compositions comprising protein l immunoglobulin binding domains for cell-specific targeting
12/01/2005WO2005113583A1 An expression system comprising operably linked rgg gene and gtfg promoter
12/01/2005WO2005113572A2 Isolated nucleic acid molecules encoding a novel phosphoprotein-darpp-32, encoded protein and uses thereof
12/01/2005WO2005113570A1 Pharmaceuticals for enhanced deliver to disease targets
12/01/2005WO2005113059A2 Disruption of the processing of the viral capsid-spacer peptide 1 protein
12/01/2005WO2005113017A2 Gfap-based gene therapy for treatment of retinal diseases
12/01/2005WO2005113015A1 Enhanced gene delivery using viral vectors
12/01/2005WO2005112994A1 Nodavirus-vlp immunization composition
12/01/2005WO2005112993A1 Vaccine for periodontal disease
12/01/2005WO2005112992A1 P. gingivalis vaccine
12/01/2005WO2005112989A1 Protease inhibitors and their therapeutic applications
12/01/2005WO2005112988A2 Methods for treating and diagnosing cancer with wnt inhibitory factor-1 (wif-1)
12/01/2005WO2005112982A1 Process for the isolation and/or purification of proteins
12/01/2005WO2005112979A2 Methods of preventing and treating alimentary mucositis
12/01/2005WO2005112971A1 Method for inhibiting angiogenesis and/or lymphangiogenesis
12/01/2005WO2005112628A2 Sptrx-3 polypeptide and nucleic acid. uses thereof in methods and compositions for evaluation of male fertility
12/01/2005WO2005112621A2 A murine model of hiv-1 infection
12/01/2005WO2005112619A2 Novel gene disruptions, compositions and methods relating thereto
12/01/2005WO2005112609A2 Promotion of somatic embryogenesis in plants by pga37 gene expression
12/01/2005WO2005112608A2 Modified plant transcription factors
12/01/2005WO2005112597A2 Transgenic plants expressing intein modified proteins and associated processes for bio-pharmaceutical production
12/01/2005WO2005112568A2 Haplotype markers and methods of using the same to determine response to treatment
12/01/2005WO2005097165A3 Il-28 and il-29 cysteine mutants for treating viral infection
12/01/2005WO2005095620A3 Methods and compositions for regulating plant stress tolerance
12/01/2005WO2005092379A3 Materials and methods for treatment of cancer
12/01/2005WO2005090589A3 Process for the production of l-amino acids using coryneform bacteria
12/01/2005WO2005089790A3 Y2/y4 selective receptor agonists for therapeutic interventions
12/01/2005WO2005089164A3 Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
12/01/2005WO2005087808A3 Growth factor binding constructs materials and methods
12/01/2005WO2005084116A8 Calcium channel variants
12/01/2005WO2005082930A3 An immunoreactive 38-kda ferric binding protein of ehrlichia canis and uses thereof
12/01/2005WO2005082928A3 Peptide analogues of gip for treatment of diabetes, insulin resistance and obesity
12/01/2005WO2005080545A3 Method for the production of recombined proteins in eukaryontic host cells
12/01/2005WO2005077969A3 Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
12/01/2005WO2005074985A3 Methods of modulating cd200 and cd200r
12/01/2005WO2005065015A3 Neutralizing antibodies and methods of use thereof
12/01/2005WO2005058938A3 Helical synthetic peptides that stimulate cellular cholesterol efflux
12/01/2005WO2005054509A3 Assay and treatment
12/01/2005WO2005051977A3 Conditional allele system
12/01/2005WO2005041868A3 Epidermal growth factor receptor modulation protects normal tissue
12/01/2005WO2005027831A3 Modulators of p-selectin glycoprotein ligand 1
12/01/2005WO2005023848A3 Adenoviral epitopes
12/01/2005WO2005005614A3 Combined b-cell and t-cell epitopes on vlp for improved vaccines
12/01/2005WO2004113497A3 Gene delivery to tumors
12/01/2005WO2004092343A3 Epha2, hypoproliferative cell disorders and epithelial and endothelial reconstitution
12/01/2005WO2004087875A3 Nucleic acid-associated proteins
12/01/2005WO2004085505A3 Long acting biologically active conjugates
12/01/2005WO2003049703A8 Chimeric infectious dna clones, chimeric porcine circoviruses and uses thereof
12/01/2005US20050268358 Plants having improved growth characteristics and a method for making the same
12/01/2005US20050268354 Nucleic acid molecules encoding cyclotide polypeptides and methods of use
12/01/2005US20050268350 Identification and purification of higher order transcription complexes from transgenic non-human animals
12/01/2005US20050268349 Transgenic mice containing brain-specific membrane-anchored protein gene disruptions
12/01/2005US20050267293 Loading solution onto a hydrophobic interaction chromatography matrix equilibrated in aqueous buffer at a salt concentration high enough to promote matrix-protein interactions, applying a gradient of decreasing salt concentration, and collecting the conjugate, leaving the unconjugated albumin
12/01/2005US20050267292 Extraction of collagen from calcified tissues
12/01/2005US20050267064 Containing unmethylated CpG dinucleotides, and an allergen; desensitization
12/01/2005US20050267062 Endothelial growth factors; antiischemic agents; neovascularization
12/01/2005US20050267058 RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (sINA)
12/01/2005US20050267057 Redirect a Th2 response to a Th1 response; treating asthma, allergies, infections, cancer immunotherapy; contain unmethylated cytosine-guanine (CpG) dinucleotides
12/01/2005US20050267050 Compositions and methods for treating mdma-induced toxicity
12/01/2005US20050267039 IL-16 antagonists
12/01/2005US20050267036 Peptide sequence derived from the C-terminus of CaV2.2. and inhibits the interaction of CaV2.2 with Mint1-PDZ1, a glutathione S transferase fusion protein; neurotransmitter-release angonists of CaV2.2, the pore-forming subunit of N-type of voltage-dependent calcium channels; antinocciceptive agents
12/01/2005US20050267035 Peptide and polypeptide inhibitors of complement C1s
12/01/2005US20050267034 Modified exendins and exendin agonists
12/01/2005US20050267031 procytotoxic agents for use in treating cancer; antitumor agents; has at least one lysine residue, modified by a peptide linkage to an amino acid residue, via the epsilon amino group
12/01/2005US20050267030 Use of deltaPKC peptides for modulation of reactive oxygen species
12/01/2005US20050267028 ligands isolated from Moraxella catarrhalis outer membrane protein which binds to carcinoembryonic antigen cell adhesion molecules (CEACAM) receptors, and inhibits bacterial adhesion to CEACAM expressing cells in vitro; drugs and vaccines used in the treatment or prophylaxis of infections
12/01/2005US20050267025 Compositions and methods for treatment of infectious and inflammatory diseases
12/01/2005US20050267024 Polypeptide, cancer therapy, neovascularization defects, retinopathies, arthritis and psoraisis
12/01/2005US20050267022 Identification of novel factors that block programmed cell death or apoptosis by targeting JNK
12/01/2005US20050267021 Cystatin C as an antagonist of TGF-beta and methods related thereto
12/01/2005US20050267020 Polypeptides derived from inducible hsp70 and pharmaceutical compositions containing the same
12/01/2005US20050266569 Regulator/promoter for tunable gene expression and metabolite sensing
12/01/2005US20050266567 Methods for generating high titer helper-free preparations of released recombinant AAV vectors
12/01/2005US20050266566 Viral vector in which gene for Sendai viral protein selected from NP, P, and L proteins is deleted or inactivated while all other gene functions are retained; use as expression vector in e.g. gene therapy; efficient system for reconstituting Sendai virus
12/01/2005US20050266562 Myeloid cell promoter and constructs containing same
12/01/2005US20050266559 Shade responsive promoter, promoter control elements, and combinations, and uses thereof
12/01/2005US20050266558 Compositions isolated from forage grasses and methods for their use
12/01/2005US20050266554 Cell culture comprising pancreatic-duodenal homoebox factor-1 (PDX1) expressing endoderm for use in cell therapy treatments for diabetes mellitus and nervous system disorders
12/01/2005US20050266550 TC-83-derived alphavirus vectors, particles and methods
12/01/2005US20050266535 Nucleotide sequences which code for the metE gene
12/01/2005US20050266534 Nucleotide sequences which code for the cstA gene
12/01/2005US20050266533 Therapeutic fusion protein with enhanced for use in prevention and treatment of cell proliferative, blood and nervous system disorders
12/01/2005US20050266532 Albumin fusion proteins
12/01/2005US20050266531 For selectively inhibiting the proliferation of stellate cells, which are important for the development of liver fibrosis upon liver injury
12/01/2005US20050266530 Cynomolgus prostate specific antigen
12/01/2005US20050266529 Determining if substance is ligand by contacting with cell and measuring modulation of intracellular calcium level; treatment of central nervous system and psychiatric disorders
12/01/2005US20050266527 Human G-protein receptor HIBEF51
1 ... 1118 1119 1120 1121 1122 1123 1124 1125 1126 1127 1128 1129 1130 1131 1132 1133 1134 1135 1136 1137 1138 ... 2916